Tuesday, April 5, 2022

Zydus Cadila completes phase 2 clinical trial in COVID-19 patients with biological therapy PegiHep


NEW DELHI: Drug firm Zydus Cadila on Thursday said it has successfully completed a phase 2 clinical trial In COVID-19 patients with its biological therapy, ‘PegiHep‘, and it will now begin phase 3 clinical trial.

In a regulatory filing, Zydus Cadila said “it has successfully completed a phase 2 clinical trial in COVID-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHep’… Based upon the results from its Phase 2 study, Zydus Cadila now plans to conduct a phase 3 clinical trial in India”.

Zydus Cadila, which is a part of the Cadila Healthcare group, said Pegylated Interferon alpha 2b significantly increased viral reduction and reduced the need for supplemental oxygen in moderate COVID-19 patients.

“We continue to look at possible treatment options that are safe and efficacious in the treatment and management of COVID-19. Pegylated Interferon alpha-2b has shown the potential to reduce virus titres when given earlier in the disease and we will like to explore this biological option further. We are hopeful of reinforcing our treatment options to fight COVID-19,” Sharvil Patel, Managing Director, Cadila Healthcare Ltd said.

Pegylated Interferon alpha-2b is not a new therapy. The product was first approved internationally in 2001 and is also included in WHO’s Essential Medicines List.

Zydus Cadila said its Pegylated Interferon alpha-2b, PegiHep, was originally approved for Hepatitis C and was launched in the Indian market in 2011.

Since then safe and efficacious drug use for this product has been demonstrated in thousands of patients, the company added.

Zydus Cadila said it had conducted this study on the approval from the Drugs Controller General of India (DCGI) to investigate the role of Pegylated Interferon alpha-2b for COVID 19. The company is also conducting a similar phase 2 trial in Mexico.

The company is also working with the US Food and Drug Administration (USFDA) to open an Investigational New Drug (IND) application for Pegylated Interferon alpha-2b in order to initiate appropriate clinical trials in the US.





Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...